BIOSYENT INC (RX.CA) Stock Fundamental Analysis
Canada - TSX-V:RX - CA0906901081 - Common Stock
11.2 CAD
-0.01 (-0.09%)
Overall RX gets a fundamental rating of 8 out of 10. We evaluated RX against 32 industry peers in the Pharmaceuticals industry. RX has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. RX has a decent growth rate and is not valued too expensively. These ratings would make RX suitable for quality investing!
1. Profitability
1.1 Basic Checks
RX had positive earnings in the past year.
In the past year RX had a positive cash flow from operations.
Each year in the past 5 years RX has been profitable.
Each year in the past 5 years RX had a positive operating cash flow.
1.2 Ratios
RX's Return On Assets of 18.99% is amongst the best of the industry. RX outperforms 100.00% of its industry peers.
The Return On Equity of RX (21.97%) is better than 100.00% of its industry peers.
RX has a Return On Invested Capital of 20.55%. This is amongst the best in the industry. RX outperforms 96.97% of its industry peers.
RX had an Average Return On Invested Capital over the past 3 years of 16.58%. This is significantly above the industry average of 7.62%.
The 3 year average ROIC (16.58%) for RX is below the current ROIC(20.55%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.99% | ||
| ROE | 21.97% | ||
| ROIC | 20.55% |
ROA(3y)15.54%
ROA(5y)14.96%
ROE(3y)18.57%
ROE(5y)17.96%
ROIC(3y)16.58%
ROIC(5y)16.4%
1.3 Margins
With an excellent Profit Margin value of 20.90%, RX belongs to the best of the industry, outperforming 96.97% of the companies in the same industry.
RX's Profit Margin has been stable in the last couple of years.
Looking at the Operating Margin, with a value of 26.67%, RX belongs to the top of the industry, outperforming 96.97% of the companies in the same industry.
RX's Operating Margin has declined in the last couple of years.
RX's Gross Margin of 78.18% is amongst the best of the industry. RX outperforms 96.97% of its industry peers.
RX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.67% | ||
| PM (TTM) | 20.9% | ||
| GM | 78.18% |
OM growth 3Y-3.53%
OM growth 5Y-2.73%
PM growth 3Y-1.85%
PM growth 5Y0.35%
GM growth 3Y0.17%
GM growth 5Y0.46%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so RX is creating value.
The number of shares outstanding for RX has been reduced compared to 1 year ago.
RX has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, RX has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 16.50 indicates that RX is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 16.50, RX belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
The Debt to FCF ratio of RX is 0.08, which is an excellent value as it means it would take RX, only 0.08 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 0.08, RX belongs to the best of the industry, outperforming 96.97% of the companies in the same industry.
RX has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.02, RX is in the better half of the industry, outperforming 75.76% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.08 | ||
| Altman-Z | 16.5 |
ROIC/WACC2.59
WACC7.94%
2.3 Liquidity
RX has a Current Ratio of 6.07. This indicates that RX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of RX (6.07) is better than 96.97% of its industry peers.
A Quick Ratio of 5.10 indicates that RX has no problem at all paying its short term obligations.
The Quick ratio of RX (5.10) is better than 96.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.07 | ||
| Quick Ratio | 5.1 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 18.57% over the past year.
The Earnings Per Share has been growing by 15.02% on average over the past years. This is quite good.
Looking at the last year, RX shows a quite strong growth in Revenue. The Revenue has grown by 16.82% in the last year.
RX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.33% yearly.
EPS 1Y (TTM)18.57%
EPS 3Y8.39%
EPS 5Y15.02%
EPS Q2Q%30.97%
Revenue 1Y (TTM)16.82%
Revenue growth 3Y6.97%
Revenue growth 5Y10.33%
Sales Q2Q%13.8%
3.2 Future
The Earnings Per Share is expected to grow by 15.80% on average over the next years. This is quite good.
The Revenue is expected to grow by 10.14% on average over the next years. This is quite good.
EPS Next Y20.96%
EPS Next 2Y19.25%
EPS Next 3Y15.8%
EPS Next 5YN/A
Revenue Next Year17.51%
Revenue Next 2Y12.24%
Revenue Next 3Y10.14%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 18.06, RX is valued on the expensive side.
Compared to the rest of the industry, the Price/Earnings ratio of RX indicates a rather cheap valuation: RX is cheaper than 84.85% of the companies listed in the same industry.
RX's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.91.
With a Price/Forward Earnings ratio of 12.62, RX is valued correctly.
Compared to the rest of the industry, the Price/Forward Earnings ratio of RX indicates a rather cheap valuation: RX is cheaper than 81.82% of the companies listed in the same industry.
RX's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.92.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.06 | ||
| Fwd PE | 12.62 |
4.2 Price Multiples
78.79% of the companies in the same industry are more expensive than RX, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, RX is valued a bit cheaper than 75.76% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.8 | ||
| EV/EBITDA | 8.78 |
4.3 Compensation for Growth
RX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of RX may justify a higher PE ratio.
RX's earnings are expected to grow with 15.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.86
PEG (5Y)1.2
EPS Next 2Y19.25%
EPS Next 3Y15.8%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 1.74%, RX has a reasonable but not impressive dividend return.
Compared to an average industry Dividend Yield of 3.63, RX pays a better dividend. On top of this RX pays more dividend than 93.94% of the companies listed in the same industry.
Compared to the average S&P500 Dividend Yield of 2.32, RX is paying slightly less dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.74% |
5.2 History
RX has been paying a dividend for less than 5 years, so it still needs to build a track record.
Dividend Growth(5Y)N/A
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
26.16% of the earnings are spent on dividend by RX. This is a low number and sustainable payout ratio.
DP26.16%
EPS Next 2Y19.25%
EPS Next 3Y15.8%
TSX-V:RX (10/24/2025, 7:00:00 PM)
11.2
-0.01 (-0.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners3.82%
Inst Owner ChangeN/A
Ins Owners17.84%
Ins Owner ChangeN/A
Market Cap128.58M
Revenue(TTM)39.51M
Net Income(TTM)8.26M
Analysts82.86
Price Target13.26 (18.39%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.74% |
Yearly Dividend0.18
Dividend Growth(5Y)N/A
DP26.16%
Div Incr Years2
Div Non Decr Years2
Ex-Date
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-1.33%
EPS NY rev (3m)-8.64%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.24%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.06 | ||
| Fwd PE | 12.62 | ||
| P/S | 3.25 | ||
| P/FCF | 10.8 | ||
| P/OCF | 10.74 | ||
| P/B | 3.42 | ||
| P/tB | 3.93 | ||
| EV/EBITDA | 8.78 |
EPS(TTM)0.62
EY5.54%
EPS(NY)0.89
Fwd EY7.92%
FCF(TTM)1.04
FCFY9.26%
OCF(TTM)1.04
OCFY9.31%
SpS3.44
BVpS3.28
TBVpS2.85
PEG (NY)0.86
PEG (5Y)1.2
Graham Number6.76
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.99% | ||
| ROE | 21.97% | ||
| ROCE | 27.4% | ||
| ROIC | 20.55% | ||
| ROICexc | 43.69% | ||
| ROICexgc | 59.68% | ||
| OM | 26.67% | ||
| PM (TTM) | 20.9% | ||
| GM | 78.18% | ||
| FCFM | 30.12% |
ROA(3y)15.54%
ROA(5y)14.96%
ROE(3y)18.57%
ROE(5y)17.96%
ROIC(3y)16.58%
ROIC(5y)16.4%
ROICexc(3y)59.42%
ROICexc(5y)88.26%
ROICexgc(3y)72.91%
ROICexgc(5y)116.75%
ROCE(3y)22.1%
ROCE(5y)21.86%
ROICexgc growth 3Y-33.84%
ROICexgc growth 5Y-15.21%
ROICexc growth 3Y-35.8%
ROICexc growth 5Y-16.72%
OM growth 3Y-3.53%
OM growth 5Y-2.73%
PM growth 3Y-1.85%
PM growth 5Y0.35%
GM growth 3Y0.17%
GM growth 5Y0.46%
F-Score7
Asset Turnover0.91
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.08 | ||
| Debt/EBITDA | 0.06 | ||
| Cap/Depr | 8.94% | ||
| Cap/Sales | 0.18% | ||
| Interest Coverage | 194.04 | ||
| Cash Conversion | 105.81% | ||
| Profit Quality | 144.1% | ||
| Current Ratio | 6.07 | ||
| Quick Ratio | 5.1 | ||
| Altman-Z | 16.5 |
F-Score7
WACC7.94%
ROIC/WACC2.59
Cap/Depr(3y)10.2%
Cap/Depr(5y)10.36%
Cap/Sales(3y)0.16%
Cap/Sales(5y)0.17%
Profit Quality(3y)95.24%
Profit Quality(5y)108.02%
High Growth Momentum
Growth
EPS 1Y (TTM)18.57%
EPS 3Y8.39%
EPS 5Y15.02%
EPS Q2Q%30.97%
EPS Next Y20.96%
EPS Next 2Y19.25%
EPS Next 3Y15.8%
EPS Next 5YN/A
Revenue 1Y (TTM)16.82%
Revenue growth 3Y6.97%
Revenue growth 5Y10.33%
Sales Q2Q%13.8%
Revenue Next Year17.51%
Revenue Next 2Y12.24%
Revenue Next 3Y10.14%
Revenue Next 5YN/A
EBIT growth 1Y26.59%
EBIT growth 3Y3.2%
EBIT growth 5Y7.32%
EBIT Next Year30.53%
EBIT Next 3Y14.1%
EBIT Next 5YN/A
FCF growth 1Y120.88%
FCF growth 3Y23.38%
FCF growth 5Y17.21%
OCF growth 1Y121.08%
OCF growth 3Y22.83%
OCF growth 5Y14.5%
BIOSYENT INC / RX.CA FAQ
What is the fundamental rating for RX stock?
ChartMill assigns a fundamental rating of 8 / 10 to RX.CA.
What is the valuation status of BIOSYENT INC (RX.CA) stock?
ChartMill assigns a valuation rating of 6 / 10 to BIOSYENT INC (RX.CA). This can be considered as Fairly Valued.
What is the profitability of RX stock?
BIOSYENT INC (RX.CA) has a profitability rating of 9 / 10.
What is the earnings growth outlook for BIOSYENT INC?
The Earnings per Share (EPS) of BIOSYENT INC (RX.CA) is expected to grow by 20.96% in the next year.
Is the dividend of BIOSYENT INC sustainable?
The dividend rating of BIOSYENT INC (RX.CA) is 3 / 10 and the dividend payout ratio is 26.16%.